| Application no. and date | 20180938.1 (espacenet) (Federated) (European Patent Register), 20170811 | | Patent/reg. no. and date | DK/EP 3733712, 20230524 | | Publication date | 20201104 | | Priority no. and date | US 201662374986 P, 20160815 | | EP pub. no. and date |
EP 3733712 20201104 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | P82883DK01 | | Inventor | WALLSTRÖM, Erik, c/o Novartis Pharma AG
Postfach
4002 Basel, CH,
KAKARIEKA WEISSKOPF, Algirdas Jonas, c/o Novartis Pharma AG
Postfach
4002 Basel, CH,
SAVELIEVA PRAZ, Marina, c/o Novartis Pharma AG
Postfach
4002 Basel, CH,
KAHN, Joseph Michael, c/o Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 39/395 (2006.01) , A61P 25/00 (2006.01) , C07K 16/28 (2006.01) | | Title | PROGRAMMER OG FREMGANGSMÅDER TIL BEHANDLING AF MULTIPEL SKLEROSE UNDER ANVENDELSE AF OFATUMUMAB | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
